Protein detail
CA2D1
Voltage-dependent calcium channel subunit alpha-2/delta-1 (Voltage-gated calcium channel subunit alpha-2/delta-1) [Cleaved into: Voltage-dependent calcium channel subunit alpha-2-1; Voltage-dependent calcium channel subunit delta-1]
Protein symbol CA2D1 | UniProt ID | EVMP score 0.25 |
Frequency 1 | Transmembrane count 1 | Protein classification FDA approved drug targetsPlasma proteinsPredicted intracellular proteinsPredicted membrane proteinsTransporters |
Basic Information
Protein Names
Voltage-dependent calcium channel subunit alpha-2/delta-1 (Voltage-gated calcium channel subunit alpha-2/delta-1) [Cleaved into: Voltage-dependent calcium channel subunit alpha-2-1; Voltage-dependent calcium channel subunit delta-1]
Protein Class
FDA approved drug targetsPlasma proteinsPredicted intracellular proteinsPredicted membrane proteinsTransporters
Protein Function
- Predicted intracellular proteins
- FDA approved drug targets:Small molecule drugs
- Transporters:Accessory Factors Involved in Transport
Transmembrane
1074..1094; Helical
Transmembrane Count
1
Ensembl
Entrez Gene Symbol
Gene Synonym
alpha2delta-1CACNA2CACNL2ALINC01112lncRNA-N3MHS3
Gene Description
Calcium voltage-gated channel auxiliary subunit alpha2delta 1
Chromosome
7
Position
81946444-82443956
Frequency
1
EVMP Score
0.25
Fluorescence & Localization
Tissue Specificheart muscleCell SpecificAlveolar cells type 2Single-Nuclei Brain SpecificfibroblastBlood Cell Specificclassical monocyteBlood Lineage Specificdendritic cells
Function & Pathway
Protein Function
- Predicted intracellular proteins
- FDA approved drug targets:Small molecule drugs
- Transporters:Accessory Factors Involved in Transport
Cellular Component
- GO:0005886 plasma membrane
- GO:0005891 voltage-gated calcium channel complex
- GO:0016529 sarcoplasmic reticulum
- GO:0048787 presynaptic active zone membrane
- GO:0070062 extracellular exosome
- GO:0098982 GABA-ergic synapse
- GO:0098992 neuronal dense core vesicle
- GO:1990454 L-type voltage-gated calcium channel complex
Molecular Function
Biological Process
KEGG
- hsa04010 MAPK signaling pathway
- KEGG:hsa04260 Cardiac muscle contraction
- KEGG:hsa04261 Adrenergic signaling in cardiomyocytes
- KEGG:hsa04921 Oxytocin signaling pathway
- KEGG:hsa05410 Hypertrophic cardiomyopathy
- KEGG:hsa05412 Arrhythmogenic right ventricular cardiomyopathy
- KEGG:hsa05414 Dilated cardiomyopathy
Reactome
Mediation Categories
Clinical-translation mediationFusion and delivery mediation
Relations & Evidence
Enzyme-Mediated Modification
0 records.
Ligand-Receptor Signaling
23 records.
| Category | Parent | Database | Transmitter | Receiver | Secreted | Plasma Membrane (Transmembrane) | Plasma Membrane (Peripheral) |
|---|---|---|---|---|---|---|---|
| plasma_membrane_transmembrane | plasma_membrane_transmembrane | OmniPath | No | No | No | Yes | No |
| cell_surface | cell_surface | OmniPath | No | No | No | Yes | No |
| transmembrane | transmembrane_predicted | Phobius | No | No | No | Yes | No |
Page 3 of 3Previous
Regulatory Interaction Network
0 records.
Protein Complex Composition
9 records.
| Component Name | Component Gene Symbols | Component UniProt ID | Stoichiometry | Database | Database IDs | References |
|---|---|---|---|---|---|---|
| Cav1.1 voltage-gated calcium channel complexCACNA2D1-CACNB1-CACNG1 variant | CACNA1SCACNA2D1CACNB1CACNG1 | P54289Q02641Q06432Q13698 | 2:1:1:1 | ComplexPortal | intact:EBI-9686737 | 151111041868823527273705147552922668020216382099 |
| Cav1.1 voltage-gated calcium channel complexCACNA2D1-CACNB2-CACNG1 variant | CACNA1SCACNA2D1CACNB2CACNG1 | P54289Q06432Q08289Q13698 | 2:1:1:1 | ComplexPortal | intact:EBI-48432343 | 272737051475529226680202 |
| Cav1.1 voltage-gated calcium channel complexCACNA2D1-CACNB3-CACNG1 variant | CACNA1SCACNA2D1CACNB3CACNG1 | P54284P54289Q06432Q13698 | 1:2:1:1 | ComplexPortal | intact:EBI-48440027 | 272737051475529226680202 |
| Cav1.1 voltage-gated calcium channel complexCACNA2D1-CACNB4-CACNG1 variant | CACNA1SCACNA2D1CACNB4CACNG1 | O00305P54289Q06432Q13698 | 1:2:1:1 | ComplexPortal | intact:EBI-48440098 | 272737051475529226680202 |
| CACNA1ACACNA2D1CACNB3 | O00555P54284P54289 | 1:1:1 | PDB | PDB:8x90PDB:8x93 | ||
| CACNA2D1HSPA4LNDUFS4NUP188 | O43181O95757P54289Q5SRE5 | 0:0:0:0 | Havugimana2012 | Havugimana2012:C_232 | ||
| CACNA1BCACNA2D1CACNB3 | P54284P54289Q00975 | 1:1:1 | PDB | PDB:7miy | ||
| CACNA1DCACNA2D1CACNB3 | P54284P54289Q01668 | 1:1:1 | PDB | PDB:7uhgPDB:8e5bPDB:8e5aPDB:8e59PDB:7uhf | ||
| CACNA1BCACNA2D1CACNB1 | P54289Q00975Q02641 | 1:1:1 | PDB | PDB:7vfsPDB:7vfwPDB:7vfv |
Isolation & Detection Technology
0 records.
Sequence, Structure & Domains
Sequences
Length
1,103
Mass
124,568
Sequence
MAAGCLLALTLTLFQSLLIGPSSEEPFPSAVTIKSWVDKMQEDLVTLAKTASGVNQLVDIYEKYQDLYTVEPNNARQLVEIAARDIEKLLSNRSKALVRLALEAEKVQAAHQWREDFASNEVVYYNAKDDLDPEKNDSEPGSQRIKPVFIEDANFGRQISYQHAAVHIPTDIYEGSTIVLNELNWTSALDEVFKKNREEDPSLLWQVFGSATGLARYYPASPWVDNSRTPNKIDLYDVRRRPWYIQGAASPKDMLILVDVSGSVSGLTLKLIRTSVSEMLETLSDDDFVNVASFNSNAQDVSCFQHLVQANVRNKKVLKDAVNNITAKGITDYKKGFSFAFEQLLNYNVSRANCNKIIMLFTDGGEERAQEIFNKYNKDKKVRVFTFSVGQHNYDRGPIQWMACENKGYYYEIPSIGAIRINTQEYLDVLGRPMVLAGDKAKQVQWTNVYLDALELGLVITGTLPVFNITGQFENKTNLKNQLILGVMGVDVSLEDIKRLTPRFTLCPNGYYFAIDPNGYVLLHPNLQPKPIGVGIPTINLRKRRPNIQNPKSQEPVTLDFLDAELENDIKVEIRNKMIDGESGEKTFRTLVKSQDERYIDKGNRTYTWTPVNGTDYSLALVLPTYSFYYIKAKLEETITQARYSETLKPDNFEESGYTFIAPRDYCNDLKISDNNTEFLLNFNEFIDRKTPNNPSCNADLINRVLLDAGFTNELVQNYWSKQKNIKGVKARFVVTDGGITRVYPKEAGENWQENPETYEDSFYKRSLDNDNYVFTAPYFNKSGPGAYESGIMVSKAVEIYIQGKLLKPAVVGIKIDVNSWIENFTKTSIRDPCAGPVCDCKRNSDVMDCVILDDGGFLLMANHDDYTNQIGRFFGEIDPSLMRHLVNISVYAFNKSYDYQSVCEPGAAPKQGAGHRSAYVPSVADILQIGWWATAAAWSILQQFLLSLTFPRLLEAVEMEDDDFTASLSKQSCITEQTQYFFDNDSKSFSGVLDCGNCSRIFHGEKLMNTNLIFIMVESKGTCPCDTRLLIQAEQTSDGPNPCDMVKQPRYRKGPDVCFDNNVLEDYTDCGGVSGLNPSLWYIIGIQFLLLWLVSGSTHRLL
Alternative Products
Event=Alternative splicing; Named isoforms=5; Name=1; Synonyms=Alpha-2a; IsoId=P54289-1; Sequence=Displayed; Name=2; Synonyms=Alpha-2b; IsoId=P54289-2; Sequence=VSP_038348, VSP_038350; Name=3; Synonyms=Alpha-2c; IsoId=P54289-3; Sequence=VSP_038349, VSP_038350; Name=4; Synonyms=Alpha-2d; IsoId=P54289-4; Sequence=VSP_038349; Name=5; Synonyms=Alpha-2e; IsoId=P54289-5; Sequence=VSP_038348
Alternative Sequence
531..554; Missing (in isoform 3 and isoform 4); 531..549; Missing (in isoform 2 and isoform 5); 644; Y -> SKKGKMKD (in isoform 2 and isoform 3)
3D Structural Models
Turn
64..66; 153..156; 405..407; 438..440; 653..655; 694..696; 717..723; 737..739; 749..751; 788..790; 1009..1012
Helix
30..52; 54..63; 75..109; 135..137; 177..185; 187..198; 238..240; 242..247; 262..264; 267..280; 312..323; 333..344; 347..349; 370..376; 397..404; 416..418; 419..430; 432..436; 494..498; 561..564; 570..579; 625..627; 640..646; 650..652; 676..688; 691..693; 699..716; 758..760; 762..769; 818..827; 828..830; 855..857; 868..870; 875..878; 880..888; 1021..1023; 1043..1046
Beta Strand
67..72; 118..120; 122..126; 127..129; 142..144; 150..152; 157..163; 165..167; 170..172; 174..176; 206..210; 215..220; 227..229; 253..258; 285..287; 288..303; 353..355; 356..362; 377..379; 382..391; 409..413; 453..455; 457..467; 470..474; 478..480; 483..493; 504..506; 511..515; 517..520; 584..593; 595..598; 600..611; 613..616; 618..624; 628..633; 637..639; 658..660; 668..670; 727..736; 743..748; 771..776; 780..785; 792..797; 800..804; 805..807; 810..816; 832..834; 846..849; 851..853; 858..866; 891..904; 972..983; 989..994; 997..999; 1001..1007; 1014..1016; 1036..1038; 1047..1049; 1072..1074
3D Structure
Electron microscopy (29)
Domain & Motif Annotations
Motif
259..263; MIDAS-like motif
Domain (CC)
The MIDAS-like motif in the VWFA domain binds divalent metal cations and is required to promote trafficking of the alpha-1 (CACNA1) subunit to the plasma membrane by an integrin-like switch.
Domain (FT)
253..430; VWFA; 446..556; Cache
Protein Families
Calcium channel subunit alpha-2/delta family
Sequence Similarities
Belongs to the calcium channel subunit alpha-2/delta family.
Clinical Relevance
Disease Involvement
Disease variantEpilepsyFDA approved drug targetsIntellectual disability
Related Diseases
Biomarker
Phase 3; Approved; Registered; Discontinued in Phase 2
Drug Targets
FDA approved drug targets
Drugs